This statistic displays a projection of the top five orphan R&D products (phase III/filed) ranked by net present value as of March 2025. Corcept's relacolirant had a net present value of 8.8 billion U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs is currently incentivized in the United States through the Orphan Drug Act of 1983.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Evaluate. (March 14, 2025). Leading orphan drugs in development (phase III/filed) by NPV as of 2025 (in billion U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 27, 2026, from /statistics/373396/forecast-of-leading-orphan-randd-drugs-by-net-present-value/
Evaluate. "Leading orphan drugs in development (phase III/filed) by NPV as of 2025 (in billion U.S. dollars)." Chart. March 14, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 27, 2026. /statistics/373396/forecast-of-leading-orphan-randd-drugs-by-net-present-value/
Evaluate. (2025). Leading orphan drugs in development (phase III/filed) by NPV as of 2025 (in billion U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 27, 2026. /statistics/373396/forecast-of-leading-orphan-randd-drugs-by-net-present-value/
Evaluate. "Leading Orphan Drugs in Development (Phase Iii/Filed) by Npv as of 2025 (in Billion U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 14 Mar 2025, /statistics/373396/forecast-of-leading-orphan-randd-drugs-by-net-present-value/
Evaluate, Leading orphan drugs in development (phase III/filed) by NPV as of 2025 (in billion U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/373396/forecast-of-leading-orphan-randd-drugs-by-net-present-value/ (last visited July 27, 2026)
Leading orphan drugs in development (phase III/filed) by NPV as of 2025 (in billion U.S. dollars) [Graph], Evaluate, March 14, 2025. [Online]. Available: /statistics/373396/forecast-of-leading-orphan-randd-drugs-by-net-present-value/
